Covalent Allosteric Probe for the Metabotropic Glutamate Receptor 2: Design, Synthesis, and Pharmacological Characterization

Covalent labeling of G protein-coupled receptors (GPCRs) by small molecules is a powerful approach to understand binding modes, mechanism of action, pharmacology, and even facilitate structure elucidation. We report the first covalent positive allosteric modulator (PAM) for a class C GPCR, the mGlu2 receptor. Three putatively covalent mGlu2 PAMs were designed and synthesized. Pharmacological characterization identified 2 to bind the receptor covalently. Computational modeling combined with receptor mutagenesis revealed T7917.29×30 as the likely position of covalent interaction. We show how this covalent ligand can be used to characterize the PAM binding mode and that it is a valuable tool compound in studying receptor function and binding kinetics. Our findings advance the understanding of the mGlu2 PAM interaction and suggest that 2 is a valuable probe for further structural and chemical biology approaches.

[1]  M. Congreve,et al.  Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs. , 2017, Trends in pharmacological sciences.

[2]  A. IJzerman,et al.  Discovery and Kinetic Profiling of 7-Aryl-1,2,4-triazolo[4,3-a]pyridines: Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2. , 2017, Journal of medicinal chemistry.

[3]  Arnau Cordomí,et al.  Molecular Switches of Allosteric Modulation of the Metabotropic Glutamate 2 Receptor. , 2017, Structure.

[4]  Arthur Christopoulos,et al.  Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity , 2017, Cell.

[5]  Shaoyong Lu,et al.  Designed covalent allosteric modulators: an emerging paradigm in drug discovery. , 2017, Drug discovery today.

[6]  J. Strelow.  A Perspective on the Kinetics of Covalent and Irreversible Inhibition , 2017, SLAS discovery : advancing life sciences R & D.

[7]  David E. Gloriam,et al.  Structural insight to mutation effects uncover a common allosteric site in class C GPCRs , 2016, Bioinform..

[8]  A. IJzerman,et al.  A covalent antagonist for the human adenosine A2A receptor , 2016, Purinergic Signalling.

[9]  J. Pin,et al.  Organization and functions of mGlu and GABAB receptor complexes , 2016, Nature.

[10]  T. Baillie,et al.  Targeted Covalent Inhibitors for Drug Design. , 2016, Angewandte Chemie.

[11]  María Lourdes Linares,et al.  Discovery of 8-Trifluoromethyl-3-cyclopropylmethyl-7-[(4-(2,4-difluorophenyl)-1-piperazinyl)methyl]-1,2,4-triazolo[4,3-a]pyridine (JNJ-46356479), a Selective and Orally Bioavailable mGlu2 Receptor Positive Allosteric Modulator (PAM). , 2016, Journal of medicinal chemistry.

[12]  W. Drevets,et al.  Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[13]  David J. Lapinsky,et al.  Clickable Photoaffinity Ligands for Metabotropic Glutamate Receptor 5 Based on Select Acetylenic Negative Allosteric Modulators. , 2016, ACS chemical biology.

[14]  K. Gregory,et al.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors. , 2016, Chemical reviews.

[15]  A. IJzerman,et al.  Molecular mechanism of positive allosteric modulation of the metabotropic glutamate receptor 2 by JNJ‐46281222 , 2016, British journal of pharmacology.

[16]  Ralf C. Kling,et al.  Development of Covalent Ligand-Receptor Pairs to Study the Binding Properties of Nonpeptidic Neurotensin Receptor 1 Antagonists. , 2016, ACS chemical biology.

[17]  A. IJzerman,et al.  Scintillation proximity assay (SPA) as a new approach to determine a ligand’s kinetic profile. A case in point for the adenosine A1 receptor , 2015, Purinergic Signalling.

[18]  Ali Jazayeri,et al.  Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). , 2015, Journal of medicinal chemistry.

[19]  G. Tresadern,et al.  Molecular determinants of positive allosteric modulation of the human metabotropic glutamate receptor 2 , 2015, British journal of pharmacology.

[20]  P. Gmeiner,et al.  Covalent molecular probes for class A G protein-coupled receptors: advances and applications. , 2015, ACS chemical biology.

[21]  A. Narayanan,et al.  Sulfonyl fluorides as privileged warheads in chemical biology , 2015, Chemical science.

[22]  Vikash K. Sinha,et al.  Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies , 2015, Journal of psychopharmacology.

[23]  A. Megens,et al.  Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813 , 2015, Pharmacology research & perspectives.

[24]  X. Langlois,et al.  Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor , 2014, Pharmacology research & perspectives.

[25]  L. Mahan,et al.  Correction to “The Kinetics of Competitive Radioligand Binding Predicted by the Law of Mass Action” , 2014, Molecular Pharmacology.

[26]  G. Tresadern,et al.  QSAR design of triazolopyridine mGlu2 receptor positive allosteric modulators. , 2014, Journal of molecular graphics & modelling.

[27]  María Lourdes Linares,et al.  Discovery of 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): a novel positive allosteric modulator of the metabotropic glutamate 2 receptor. , 2014, Journal of medicinal chemistry.

[28]  C. Zhang,et al.  Covalent agonists for studying G protein-coupled receptor activation , 2014, Proceedings of the National Academy of Sciences.

[29]  A. Doré,et al.  Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain , 2014, Nature.

[30]  Jens Meiler,et al.  Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator , 2014, Science.

[31]  A. Megens,et al.  Pharmacological Characterization of JNJ-40068782, a New Potent, Selective, and Systemically Active Positive Allosteric Modulator of the mGlu2 Receptor and Its Radioligand [3H]JNJ-40068782 , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[32]  E. Haaksma,et al.  Design and pharmacological characterization of VUF14480, a covalent partial agonist that interacts with cysteine 983.36 of the human histamine H4 receptor , 2013, British journal of pharmacology.

[33]  Albert C. Pan,et al.  The Dynamic Process of β2-Adrenergic Receptor Activation , 2013, Cell.

[34]  María Lourdes Linares,et al.  Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. , 2012, Journal of medicinal chemistry.

[35]  María Lourdes Linares,et al.  Discovery of 1,4-disubstituted 3-cyano-2-pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor. , 2012, Journal of medicinal chemistry.

[36]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[37]  F. Nicoletti,et al.  Metabotropic glutamate receptors: From the workbench to the bedside , 2011, Neuropharmacology.

[38]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.

[39]  P. Conn,et al.  Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.

[40]  T. Kenakin,et al.  Determining the Potency and Molecular Mechanism of Action of Insurmountable Antagonists , 2006, Journal of Pharmacology and Experimental Therapeutics.

[41]  L. Cuisset,et al.  The Effects of Sodium Butyrate on Transcription Are Mediated through Activation of a Protein Phosphatase* , 1997, The Journal of Biological Chemistry.